PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression
Yuhong Jiang, Xin Zhuo, Yue Wu, Xiujuan Fu, Canquan Mao
Topics & Concepts
OsimertinibMAPK/ERK pathwayCancer researchTransactivationGefitinibPharmacologyMedicineChemistryPhosphorylationEpidermal growth factor receptorReceptorInternal medicineErlotinibBiochemistryGene expressionGeneLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancerHER2/EGFR in Cancer Research